Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?

Mayo Clinic proceedings - 1 Feb 2009

Jabbour Elias, Cortes Jorge E, Kantarjian Hagop M

Abstract excerpt

Treatment responses to imatinib vary among patients with chronic myeloid leukemia (CML), and definitions of treatment failure and suboptimal response have been published. This article discusses monitoring and treatment of patients with CML after failure of or suboptimal response to imatinib therapy. We reviewed articles listed on PubMed from January 1, 2002, to July 31, 2008, and abstracts from the 2007 Annual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Dasatinib
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Thiazoles

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 19181650
DOI: 10.4065/84.2.161
PMCID: PMC2664587

Genes

BCR
ABL1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?PMID 19181650Read ↗

Treatment of chronic myeloid leukemia when imatinib fails.Semantic proximity Read ↗

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.Semantic proximity Read ↗

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?Semantic proximity Read ↗

Treatment selection after imatinib resistance in chronic myeloid leukemia.Semantic proximity Read ↗

Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?Semantic proximity Read ↗

Clinical resistance to imatinib: mechanisms and implications.Semantic proximity Read ↗

Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications.Semantic proximity Read ↗

The development of imatinib as a therapeutic agent for chronic myeloid leukemiaSemantic proximity Read ↗

Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.Semantic proximity Read ↗

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia.Semantic proximity Read ↗

Practical considerations for monitoring patients with chronic myeloid leukemia.Semantic proximity Read ↗

Response definitions and European Leukemianet Management recommendations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.